Evonik Charts a New Strategic Course Amid Financial Adjustments

Evonik hits 2025 EBITDA target but sees sales decline. Announces 10% price hike, €400M cost cuts, 2,000 job reductions, and a new variable dividend policy for 2026.

The German specialty chemicals group Evonik has unveiled a series of strategic and financial adjustments, presenting a mixed picture of meeting near-term targets while adopting a more cautious outlook for the coming year. The company is implementing global price increases, a significant cost-cutting initiative, and a fundamental shift in its dividend policy.

Financial Performance: Hitting Profit Targets Amid Revenue Decline

For the 2025 fiscal year, Evonik confirmed its preliminary results, meeting its key profit guidance. Adjusted EBITDA came in at €1.87 billion, aligning with the communicated target of approximately €1.9 billion.

However, this profitability was achieved against a backdrop of declining sales. Group revenue fell by 7% to €14.1 billion. Despite the top-line pressure, net income improved to €265 million, up from €222 million in the prior year. The company also demonstrated strong cash generation, with a free cash flow of €695 million driving its cash conversion rate to 37%, hitting the upper end of its target range.

Segment performance remained challenging. The Advanced Technologies division faced pressure from lower selling prices and negative currency effects. Similarly, the Custom Solutions unit was impacted by weaker volumes and adverse foreign exchange movements.

Strategic Levers: Price Hikes and a Major Restructuring Program

Shortly after its annual results conference, Evonik announced immediate operational actions. The company instituted a global net price increase of 10% for its MetAMINO® product (DL-Methionine 99%, feed grade). According to the firm, existing contracts and supply agreements will remain unaffected. This move signals a strategic pivot toward margin protection in an environment where volume growth is becoming more difficult.

This pricing action is flanked by a comprehensive restructuring initiative dubbed "Evonik Tailor Made." Upon completion in 2026, the program is expected to generate annual savings of approximately €400 million, with around 80% stemming from personnel measures. The plan includes cutting up to 2,000 positions globally, with roughly 1,500 of those in Germany. The company's streamlined two-segment structure, implemented in April 2025, is intended to accelerate decision-making alongside these cuts.

Revised Outlook and a Flexible Dividend Framework

For the current 2026 fiscal year, Evonik maintains a broad adjusted EBITDA forecast range of €1.7 to €2.0 billion. Its revenue outlook, however, has been tempered. The company now anticipates sales between €13.5 and €14.5 billion, a more cautious projection than previously indicated.

A major strategic shift concerns shareholder returns. Evonik will adopt a variable dividend policy, with future payouts set to range between 40% and 60% of adjusted net income. This new framework will first be applied to the 2026 financial year. As a transitional measure for 2025, the management board will propose a dividend of €1.00 per share at the Annual General Meeting on June 3, 2026, down from €1.17 previously.

Market sentiment continues to reflect the challenging environment. Shares closed at €13.82 on Friday, marking a decline of 7.25% over the preceding 30 days. The notably low Relative Strength Index (RSI) of 15.8 underscores the recent strong downward momentum in the stock.

Looking ahead, Evonik will publish its annual report in early March, followed by the Q1 2026 quarterly statement on May 8. The new dividend policy will be officially presented to shareholders for explanation at the Annual General Meeting on June 3.